For research use only.
Catalog No.S1356 Synonyms: UCB-L059, SIB-S1
Molecular Weight(MW): 170.21
Levetiracetam is an anticonvulsant medication used to treat epilepsy.
1 Customer Review
Levetiracetam reduces DNA, synaptic, and neurite damage caused by Dox. (A) An example of cortical cultures pre-treated with 5 μ M Lev and then Dox (0.01 μ M, overnight), fixed and stained with antibodies against MAP2c. Scale bar is 20 μ m. (B) Cortical neurons at 28–32 DIV were pre-treated with 5 μ M Lev, and then a vehicle or with Dox (0.01 μ M for 3 days, or 0.1 μ M, overnight) was added. Neurons were fixed, and stained for MAP2c, synapsin, and with the Hoechst dye, and imaged. Note that red MAP2c staining also includes Dox's red fluorescence. (C) Synaptically developed primary cortical cultures at 28−32 DIV were pretreated with 5 mM Lev, and then a vehicle or with Dox (0.01 μM for 3 days, or 0.1 μM, overnight) was added. Neurons were then fixed, and stained with antibodies against γH2A.X and MAP2c, and with the Hoechst dye. Blue staining was used by the algorithm to identify and analyze γH2A.X.
Sci Rep, 2016, 6:25705.. Levetiracetam purchased from Selleck.
Purity & Quality Control
Choose Selective Calcium Channel Inhibitors
|Description||Levetiracetam is an anticonvulsant medication used to treat epilepsy.|
Levetiracetam and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for Levetiracetam binding.  Levetiracetam irreversibly inhibits the high-voltage-activated (HVA) calcium current by approximately 18% on the average in freshly isolated CA1 hippocampal neurons of rats. Levetiracetam selectively inhibits N-type Ca2+ channels of CA1 pyramidal hippocampal neurons.  Levetiracetam reverses the inhibitory effect of DMCM on GABA-elicited currents in hippocampal neurons. 
|In vivo||Levetiracetam (17 mg/kg) produces a potent suppression of sound-induced clonic convulsions in mice, and this protective effect is significantly abolished by co-administration of the beta-carboline FG 7142.  Levetiracetam exerts potent anticonvulsant activity against both focal and secondarily generalized seizures in fully amygdala-kindled rats, i.e. , a model of temporal lobe epilepsy. Levetiracetam (13 mg/kg, 27 mg/kg or 54 mg/kg, i.p.) dose-dependently suppresses the increase in seizure severity and duration induced by repeated amygdala stimulation. Levetiracetam has a relatively short half-life (about 2-3 hours) in rats.  Levetiracetam (5.4 mg/kg to 96 mg/kg i.p.) dose-dependently inhibits both wild running and tonic-clonic convulsions in the audiogenic-seizure prone rat. Levetiracetam markedly suppresses spontaneous spike-and-wave discharge (SWD) but leaves the underlying EEG trace normal in the GAERS model of petit mal epilepsy. |
-  Gigant B, et al. Nature, 2005, 435(7041), 519-522.
-  Lukyanetz EA, et al. Epilepsia, 2002, 43(1), 9-18.
-  Rigo JM, et al. Br J Pharmacol, 2002, 136(5), 659-672.
|In vitro||DMSO||34 mg/mL (199.75 mM)|
|Water||34 mg/mL (199.75 mM)|
|Ethanol||34 mg/mL (199.75 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT04317807||Not yet recruiting||Drug: Levetiracetam Pill|Other: Placebo||Early Psychosis||NYU Langone Health||July 2020||Phase 2|
|NCT04117425||Not yet recruiting||Biological: biological collection||Epilepsy in Pregnancy||Assistance Publique - Hôpitaux de Paris||May 2020||Not Applicable|
|NCT04172311||Recruiting||Other: Modified Atkins Diet|Drug: Levetiracetam||Refractory Childhood Epilepsy||Lady Hardinge Medical College||November 14 2019||Phase 2|Phase 3|
|NCT03489044||Active not recruiting||Drug: Levetiracetam|Drug: Placebo Oral Tablet||Alzheimer Disease|Epilepsy||University of Oxford|Oxford University Hospitals NHS Trust|Oxford Health NHS Foundation Trust|Northumberland Tyne and Wear NHS Foundation Trust|UCB Pharma||October 28 2018||Phase 2|
|NCT02229123||Unknown status||Drug: Intravenous Levetiracetam||Neonatal Seizures||University Hospital Tours|European Georges Pompidou Hospital|Rennes University Hospital|University of Paris 5 - Rene Descartes||February 27 2018||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.